13F Holdings
中文EN

APRE Aprea Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1781983 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-8.5%
TTM EPS YoY73.1%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-62.8%
ROA-53.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.1%
Debt / equity0.00x
Current ratio9.67x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.90x
Accruals ratio-5.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$3.34M$2.46M$1.61M$1.01M$1.64M$1.91M$2.48M$2.36M
SG&A expense$1.83M$1.57M$1.82M$1.64M$1.48M$1.59M$1.76M$1.07M
Operating income-$5.17M-$4.03M-$3.43M-$2.64M-$3.12M-$3.39M-$4.09M-$3.23M
Income tax$0$0$0$0$0$0$0$0
Net income-$4.81M-$3.59M-$3.29M-$2.46M-$2.97M-$3.24M-$3.93M-$2.89M
EBITDA-$5.17M-$4.03M-$3.42M-$2.64M-$3.11M-$3.38M-$4.08M-$3.22M
EPS (basic)-0.09-0.07-0.22—-0.47-0.53-0.66—
EPS (diluted)-0.09-0.07-0.22—-0.47-0.53-0.66—
Weighted avg. shares (diluted)53.68M53.48M14.69M—6.37M6.08M5.99M—
Balance sheet
Cash & equivalents$37.85M$41.23M$46.47M$14.60M$13.72M$16.53M$19.28M$22.89M
Current assets$38.44M$41.91M$47.25M$15.56M$13.94M$16.93M$19.83M$23.58M
PP&E, net$62,443$64,033$54,379$59,807$65,236$70,665$76,093$81,522
Total assets$38.81M$42.29M$47.61M$15.93M$14.32M$17.31M$20.22M$23.98M
Current liabilities$3.97M$3.09M$5.30M$2.76M$2.68M$3.17M$3.36M$3.36M
Total liabilities$4.70M$3.82M$6.02M$3.49M$3.41M$3.90M$4.67M$4.67M
Shareholders' equity$34.11M$38.47M$41.59M$12.44M$10.91M$13.41M$15.55M$19.31M
Shares outstanding14.19M12.39M11.98M8.19M5.98M5.75M5.51M5.48M
Cash flow statement
Operating cash flow-$3.73M-$3.28M-$2.76M-$2.96M-$3.17M-$3.13M-$3.63M-$3.51M
Capital expenditure$1——————$0
Free cash flow-$3.73M——————-$3.51M
Investing cash flow-$1——————$0
Financing cash flow$342,000-$1.94M$34.62M$3.84M$357,940$384,879$55,849$134,405
Depreciation & amortization$5,905$5,746$5,428$5,429$5,429$5,428$5,429$5,428
Stock-based compensation$100,000$100,000——$100,000$100,000$100,000—

Free plan shows the latest 8 periods; Pro shows all 33 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.